2018
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial
Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology Of Aging 2018, 70: 117-124. PMID: 30007160, PMCID: PMC6503670, DOI: 10.1016/j.neurobiolaging.2018.05.033.Peer-Reviewed Original ResearchConceptsDose of guanfacineQuality of lifeZ-scoreCognitive functionPrefrontal cognitive dysfunctionCommon adverse eventsPrimary outcome measureRandomized clinical trialsGlobal functionOlder participantsHealthy older participantsPrefrontal cognitive functionDry mouthAdverse eventsAgonist guanfacineClinical trialsGuanfacine treatmentCognitive dysfunctionMean changeOutcome measuresPlaceboGuanfacineOlder individualsWeeksDose
2007
Aripiprazole in the treatment of the psychosis prodrome
Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH. Aripiprazole in the treatment of the psychosis prodrome. The British Journal Of Psychiatry. Supplement 2007, 191: s96-s101. PMID: 18055946, DOI: 10.1192/bjp.191.51.s96.Peer-Reviewed Original ResearchConceptsPsychosis prodromeMixed-effects repeated-measures analysisShort-term efficacySymptom total scoreSingle-site trialRepeated-measures analysisAripiprazole treatmentAdverse eventsFinal visitSafety profilePromising efficacyProdromal phasePsychotic disordersScale scoreBaseline levelsWeight gainFirst weekProdromeTotal scoreAripiprazoleTreatmentNeuropsychological measuresPreliminary evidenceWeeksEfficacy